JP2020519742A5 - - Google Patents

Download PDF

Info

Publication number
JP2020519742A5
JP2020519742A5 JP2019563248A JP2019563248A JP2020519742A5 JP 2020519742 A5 JP2020519742 A5 JP 2020519742A5 JP 2019563248 A JP2019563248 A JP 2019563248A JP 2019563248 A JP2019563248 A JP 2019563248A JP 2020519742 A5 JP2020519742 A5 JP 2020519742A5
Authority
JP
Japan
Prior art keywords
dextran sulfate
pharmaceutically acceptable
acceptable salt
use according
range
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019563248A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020519742A (ja
JP6817466B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/SE2018/050506 external-priority patent/WO2018212708A1/en
Publication of JP2020519742A publication Critical patent/JP2020519742A/ja
Publication of JP2020519742A5 publication Critical patent/JP2020519742A5/ja
Application granted granted Critical
Publication of JP6817466B2 publication Critical patent/JP6817466B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019563248A 2017-05-17 2018-05-16 緑内障の治療 Active JP6817466B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
SE1750615 2017-05-17
SE1750615-5 2017-05-17
US201762555848P 2017-09-08 2017-09-08
US62/555,848 2017-09-08
PCT/SE2018/050506 WO2018212708A1 (en) 2017-05-17 2018-05-16 Treatment of glaucoma

Publications (3)

Publication Number Publication Date
JP2020519742A JP2020519742A (ja) 2020-07-02
JP2020519742A5 true JP2020519742A5 (https=) 2020-08-13
JP6817466B2 JP6817466B2 (ja) 2021-01-20

Family

ID=62245395

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019563248A Active JP6817466B2 (ja) 2017-05-17 2018-05-16 緑内障の治療

Country Status (12)

Country Link
US (1) US11291684B2 (https=)
EP (1) EP3532072B1 (https=)
JP (1) JP6817466B2 (https=)
KR (1) KR102331421B1 (https=)
CN (1) CN110621320B (https=)
CA (1) CA3063851C (https=)
DK (1) DK3532072T3 (https=)
ES (1) ES2777836T3 (https=)
IL (1) IL270362B (https=)
PL (1) PL3532072T3 (https=)
PT (1) PT3532072T (https=)
RU (1) RU2759998C2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3074987A1 (en) * 2017-09-08 2019-03-14 Tx Medic Ab New use of dextran sulfate
GB202008919D0 (en) * 2020-06-11 2020-07-29 Univ Birmingham Polysaccharide conpositions and therapeutic gels
CN115531417B (zh) * 2022-11-14 2024-04-09 青岛海尔生物科技有限公司 ITGA6阳性iPSC源小梁网类细胞在制备治疗高眼压疾病药物中的应用及筛选方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4238482A (en) * 1978-09-29 1980-12-09 Peyman Gholam A Intraocular infusion irrigation solution and method
DE3705669A1 (de) 1987-02-21 1988-09-01 Thomae Gmbh Dr K Verwendung von dextransulfat zur herstellung eines arzneimittels zur behandlung und prophylaxe von gefaessverengungen und gefaessverschluessen
JPH02223525A (ja) * 1988-11-16 1990-09-05 Takeda Chem Ind Ltd 血管新生阻害剤
US5135920A (en) * 1988-11-16 1992-08-04 Takeda Chemical Industries, Ltd. Angiostatic agents
US5227372A (en) 1990-03-07 1993-07-13 Children's Medical Center Corporation Method for retaining ophthalmological agents in ocular tissues
CA2020199C (en) 1990-06-29 2002-08-20 Daniel Bar-Shalom Uses of sulphated sugars
US5605938A (en) 1991-05-31 1997-02-25 Gliatech, Inc. Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
CA2331620A1 (en) 1998-05-11 1999-11-18 The Endowment For Research In Human Biology, Inc. Use of neomycin for treating angiogenesis-related diseases
GB9917092D0 (en) 1999-07-22 1999-09-22 Ml Lab Plc Treatment of angiogenesis-dependent conditions
WO2005110438A2 (en) 2004-04-15 2005-11-24 Massachusetts Institute Of Technology Methods and products related to the intracellular delivery of polysaccharides
SE0401182D0 (sv) 2004-05-05 2004-05-05 Q Med Ab Novel use of a viscoelastic composition
US20060154894A1 (en) 2004-09-15 2006-07-13 Massachusetts Institute Of Technology Biologically active surfaces and methods of their use
WO2007002139A2 (en) 2005-06-22 2007-01-04 The Trustees Of The University Of Pennsylvania Neuroprotection of retinal ganglion cells
US20140186339A1 (en) * 2006-10-27 2014-07-03 Lpath, Inc. Compositions and methods for treating ocular diseases and conditions
US20130273096A1 (en) 2011-10-05 2013-10-17 Bruce A. Daniels Therapeutic Sulfated Polysaccharides, Compositions Thereof, and Methods for Treating Patients
EP3142684A4 (en) * 2014-05-12 2018-05-23 Purdue Research Foundation Selectin and icam/vcam peptide ligand conjugates
WO2015190989A1 (en) 2014-06-12 2015-12-17 Tx Medic Ab The use of dextran sulfate having an average molecular weight below 10000 da for inducing angiogenisis in a subject
SE538503C2 (en) 2014-11-11 2016-08-16 Tx Medic Ab New dextran sulfate
SE539575C2 (en) * 2015-07-30 2017-10-17 Tx Medic Ab Dextran sulfate for use in treating, inhibiting or preventing cardiac fibrosis
CN107137421A (zh) 2017-05-25 2017-09-08 青岛市中心医院 硫酸葡聚糖在制备抑制角膜血管新生药物中的应用

Similar Documents

Publication Publication Date Title
JP2020519742A5 (https=)
JP2010534225A5 (https=)
AU2011334617B2 (en) Folic acid - Ramipril combination: cellprotective, neuroprotective and retinoprotective ophtalmologic compositions
JP2013530127A5 (https=)
JP2014506927A5 (https=)
CA2678587A1 (en) O-desulfated heparins treating acute exacerbations of chronic obstructive pulmonary disease
AR089962A1 (es) Composiciones farmaceuticas oftalmicas y metodos para su elaboracion y uso
FI3982963T3 (fi) Koostumus, johon sisältyy pridopidiini ja sen analogi, huntingtonin taudin ja sen oireitten hoitoa varten
JP2018521086A5 (https=)
JP2007518769A5 (ja) 内皮前駆細胞の刺激並びに臓器の再生及び末端器官障害の進行の抑制のための低用量エリスロポエチンの使用
RU2019136633A (ru) Лечение глаукомы
JP2013543004A5 (https=)
US11484513B2 (en) Salbutamol-containing ophthalmic medicament
WO2018100469A1 (en) Composition for the treatment of gastroesophageal reflux comprising hyaluronic acid
WO2021068962A1 (zh) 一种用于血管新生、淋巴管新生相关疾病的多肽及其用途
PH12022552763A1 (en) Medical use of daridorexant
TWI809338B (zh) 抗發炎或抗血管生成之醫藥組成物
CN108815171B (zh) 25-羟基胆固醇在制备治疗或预防心肌梗死的药物中的应用
WO2014186344A2 (en) Methods and agents for treating tyrosinase-positive albinism
CN105560219B (zh) 芬戈莫德或其盐在治疗囊肿性疾病中的用途
JP2015507478A5 (https=)
WO2013111729A1 (ja) 医薬組成物及びこれを用いた薬用化粧品
RU2017135273A (ru) Пирролидон-карбоновая кислота (рса) для офтальмологического применения
Kurysheva The new advantages and perspectives of Latanoprost (Xalatan, Pfizer, USA) treatment in pseudoexfoliation glaucoma
BR102012001875A2 (pt) composiÇço farmacÊuticas contendo ativadores do eixo enzima conversora de angiotensina 2/angiotensina-(1-7)/receptor mas para tratamento de patologias oculares